Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
Genedrive PLC (AIM:GDR) Proposed REX Retail Offer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the
Genedrive PLC (AIM:GDR) NICE recommends the Genedrive CYP2C19-ID Kit
NICE recommends the Genedrive® CYP2C19-ID Kit
Genedrive PLC (AIM:GDR) Initial overseas orders of MT-RNR1 ID kit
Initial overseas orders of the Genedrive® MT-RNR1 ID Kit
Genedrive PLC (AIM:GDR) Multi-partner grant awarded
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
The former chief scientist of China concedes that the theory of a laboratory leak causing Covid cannot be entirely dismissed.
The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
Genedrive PLC – NICE recommends CYP2C19 genotyping
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
According to the US Department of Energy, it is probable that Covid-19 originated from a laboratory leak.
According to the Wall Street Journal, a recently updated and classified 2021 US Department of Energy study, provided to senior American lawmakers and the White House, suggests that the virus
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for